203 related articles for article (PubMed ID: 11751502)
1. Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer.
Fedarko NS; Jain A; Karadag A; Van Eman MR; Fisher LW
Clin Cancer Res; 2001 Dec; 7(12):4060-6. PubMed ID: 11751502
[TBL] [Abstract][Full Text] [Related]
2. Serum bone sialoprotein in patients with primary breast cancer is a prognostic marker for subsequent bone metastasis.
Diel IJ; Solomayer EF; Seibel MJ; Pfeilschifter J; Maisenbacher H; Gollan C; Pecherstorfer M; Conradi R; Kehr G; Boehm E; Armbruster FP; Bastert G
Clin Cancer Res; 1999 Dec; 5(12):3914-9. PubMed ID: 10632320
[TBL] [Abstract][Full Text] [Related]
3. Nonspecific cross-reacting antigen 50/90 is elevated in patients with breast, lung, and colon cancer.
Allard WJ; Neaman IE; Elting JJ; Barnett TR; Yoshimura H; Fritsche HA; Yeung KK
Cancer Res; 1994 Mar; 54(5):1227-34. PubMed ID: 8118811
[TBL] [Abstract][Full Text] [Related]
4. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival.
Singhal H; Bautista DS; Tonkin KS; O'Malley FP; Tuck AB; Chambers AF; Harris JF
Clin Cancer Res; 1997 Apr; 3(4):605-11. PubMed ID: 9815727
[TBL] [Abstract][Full Text] [Related]
5. Small integrin binding ligand N-linked glycoprotein gene family expression in different cancers.
Fisher LW; Jain A; Tayback M; Fedarko NS
Clin Cancer Res; 2004 Dec; 10(24):8501-11. PubMed ID: 15623631
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma.
Koopmann J; Fedarko NS; Jain A; Maitra A; Iacobuzio-Donahue C; Rahman A; Hruban RH; Yeo CJ; Goggins M
Cancer Epidemiol Biomarkers Prev; 2004 Mar; 13(3):487-91. PubMed ID: 15006928
[TBL] [Abstract][Full Text] [Related]
7. Osteoprotegerin and osteopontin serum values in postmenopausal advanced breast cancer patients treated with anastrozole.
Martinetti A; Bajetta E; Ferrari L; Zilembo N; Seregni E; Del Vecchio M; Longarini R; La Torre I; Toffolatti L; Paleari D; Bombardieri E
Endocr Relat Cancer; 2004 Dec; 11(4):771-9. PubMed ID: 15613451
[TBL] [Abstract][Full Text] [Related]
8. Elevated plasma osteopontin levels in patients with hepatocellular carcinoma.
Kim J; Ki SS; Lee SD; Han CJ; Kim YC; Park SH; Cho SY; Hong YJ; Park HY; Lee M; Jung HH; Lee KH; Jeong SH
Am J Gastroenterol; 2006 Sep; 101(9):2051-9. PubMed ID: 16848813
[TBL] [Abstract][Full Text] [Related]
9. Expression of bone matrix proteins in human breast cancer: potential roles in microcalcification formation and in the genesis of bone metastases.
Bellahcène A; Castronovo V
Bull Cancer; 1997 Jan; 84(1):17-24. PubMed ID: 9180854
[TBL] [Abstract][Full Text] [Related]
10. Tumor cells are the source of osteopontin and bone sialoprotein expression in human breast cancer.
Sharp JA; Sung V; Slavin J; Thompson EW; Henderson MA
Lab Invest; 1999 Jul; 79(7):869-77. PubMed ID: 10418827
[TBL] [Abstract][Full Text] [Related]
11. Clinical usefulness of serum pyridinoline cross-linked carboxyterminal telopeptide of type I collagen for diagnosis of bone metastases in patients with primary lung cancer.
Yokoyama T; Yamamoto M; Shima K; Suzuki K; Sako C; Ito G; Kume M; Maeda M
Respirology; 2005 Jun; 10(3):300-4. PubMed ID: 15955141
[TBL] [Abstract][Full Text] [Related]
12. Serum levels and biochemical characteristics of cancer-associated antigen CA-549, a circulating breast cancer marker.
Bray KR; Koda JE; Gaur PK
Cancer Res; 1987 Nov; 47(22):5853-60. PubMed ID: 2444335
[TBL] [Abstract][Full Text] [Related]
13. Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton.
Mountzios G; Dimopoulos MA; Bamias A; Papadopoulos G; Kastritis E; Syrigos K; Pavlakis G; Terpos E
Acta Oncol; 2007; 46(2):221-9. PubMed ID: 17453373
[TBL] [Abstract][Full Text] [Related]
14. Utility of osteopontin as a biomarker in recurrent epithelial ovarian cancer.
Brakora KA; Lee H; Yusuf R; Sullivan L; Harris A; Colella T; Seiden MV
Gynecol Oncol; 2004 May; 93(2):361-5. PubMed ID: 15099946
[TBL] [Abstract][Full Text] [Related]
15. [Evaluation of serum pepsinogen I , II and osteopontin co-detection in gastric cancer screening].
Gong YH; Sun LP; Yuan Y
Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):691-3. PubMed ID: 17274377
[TBL] [Abstract][Full Text] [Related]
16. The pretreatment plasma level and diagnostic utility of M-CSF in benign breast tumor and breast cancer patients.
Ławicki S; Szmitkowski M; Wojtukiewicz M
Clin Chim Acta; 2006 Sep; 371(1-2):112-6. PubMed ID: 16631152
[TBL] [Abstract][Full Text] [Related]
17. Preoperative plasma osteopontin level as a biomarker complementary to carbohydrate antigen 125 in predicting ovarian cancer.
Nakae M; Iwamoto I; Fujino T; Maehata Y; Togami S; Yoshinaga M; Douchi T
J Obstet Gynaecol Res; 2006 Jun; 32(3):309-14. PubMed ID: 16764622
[TBL] [Abstract][Full Text] [Related]
18. [PTHrP and bone sialoprotein as prognostic markers for developing bone metastases in breast cancer patients].
Loibl S; Königs A; Kaufmann M; Costa SD; Bischoff J
Zentralbl Gynakol; 2006 Dec; 128(6):330-5. PubMed ID: 17213971
[TBL] [Abstract][Full Text] [Related]
19. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
[TBL] [Abstract][Full Text] [Related]
20. Prospective evaluation of prostate cancer detection by prostate specific antigen related parameters: comparison in serum and plasma samples.
Egawa S; Suyama K; Matsumoto K; Kuwao S; Baba S
J Urol; 2002 Jan; 167(1):97-102. PubMed ID: 11743284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
